#United States #Plano #U.S. Renal Care #dialysis innovations #kidney treatment

U.S. Renal Care's Efforts at ASN Kidney Week 2026

Renowned for its commitment to kidney care, U.S. Renal Care (USRC) recently showcased groundbreaking research at the American Society of Nephrology's (ASN) Kidney Week 2026. With a focus on addressing critical issues in nephrology, the presentations highlighted eight studies that aim to transform the management of kidney disease, particularly for dialysis patients.

The pivotal research presented included topics such as anemia management and the prevention of catheter-related bloodstream infections, which significantly impact the health of individuals undergoing dialysis. As the largest privately held kidney care provider in the United States, USRC is at the forefront of implementing innovative therapies that not only enhance clinical outcomes but also improve patients’ quality of life.

Geoffrey A. Block, USRC's Associate Chief Medical Officer and Senior Vice President of Clinical Research and Medical Affairs, emphasized the provider’s dedication to enhancing kidney care. He stated, "We believe it is our privilege and our obligation to advance the care of patients with kidney disease through the conduct of high-quality, meaningful clinical research." This underscores USRC's commitment to being an industry leader in nephrology and clinical research, striving for excellence in patient outcomes.

The studies unveiled at ASN Kidney Week cover a broad spectrum of challenges faced by patients. One of the highlight presentations focused on Vadadustat's efficiency when administered three times weekly for treating anemia in hemodialysis patients. This late-breaking high-impact clinical trial aimed to shed light on treatment options that are both effective and patient-friendly.

In addition, USRC's Kidney Research team explored the efficacy of Upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. The trials, consisting of two randomized controlled clinical trials, sought to gather substantial evidence supporting new therapeutic approaches in nephrology.

A significant study also examined the alarming issue of nurse shortages in home dialysis settings. Investigators surveyed various factors affecting recruitment and retention of home dialysis nurses across the United States, aiming to propose actionable solutions to bridge this gap in patient care.

Moreover, a late-breaking poster presentation explored the real-world effectiveness of a Taurolidine/Heparin Catheter Lock Solution, highlighting its potential to reduce complications related to central venous catheters in hemodialysis patients. This study signifies an important step forward in minimizing risks associated with dialysis treatments.

Further research evaluated the association between using DefenCath as a catheter locking solution and a decline in catheter-related bloodstream infections in real-world dialysis settings. This work is crucial as it directly addresses prevalent safety concerns in dialysis practices.

USRC’s commitment to integrate cutting-edge therapies culminates in ongoing clinical trials, such as a phase 2b study focused on AP306 for managing hyperphosphatemia in patients on maintenance hemodialysis.

In addition, the research team is analyzing biomarker profiles in patients with secondary hyperparathyroidism and the treatment effects of Upacicalcet, contributing to the understanding of chronic kidney disease-mineral bone disorders. This multifaceted research approach encapsulates USRC's innovation and dedication within the nephrology landscape.

Overall, U.S. Renal Care's remarkable efforts at ASN Kidney Week 2026 highlight a profound commitment to enhancing kidney care through meaningful clinical research, aligning with their mission to support over 37,000 individuals living with kidney disease across the nation. As the organization continues to grow and evolve, it remains steadfast in its pursuit of clinical excellence and innovation, making strides toward better health outcomes for patients with kidney disease in the United States.

For more insights about their programs and clinical trials, visit USRenalCare.com.